Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion

Background: EGFR and ERBB2 exon 20 insertion (Ex20ins) account for a small fraction of patients with EGFR mutations. The efficacy of immune checkpoint inhibitors (ICIs) for these patients was still controversial. Methods: This retrospective study enrolled lung cancer patients harboring either EGFR or ERBB2 Ex20ins mutations. All the patients were treated with platinum-based chemotherapy plus ICIs, or platinum-based chemotherapy. The demographic features and clinical outcome of each patient were reviewed and analyzed. Results: When treated with immunochemotherapy, patients with EGFR/ERBB2 Ex20ins mutations (<i<n</i< = 31) had poor PFS compared with those without EGFR mutations (<i<n</i< = 141, 5.0 mon and 11.2 mon, <i<p</i< < 0.001). When compared with those with EGFR classic mutations who received immunotherapy as the salvage therapy (<i<n</i< = 24), these patients with EGFR/ERBB2 Ex20ins mutations had similar PFS (5.0 mon and 4.1 mon, <i<p</i< = 0.625), ORR (37.5% vs. 48.4%), and DCR (70.8% vs. 77.4%). In the patients with EGFR/ERBB2 Ex20ins mutations, the PFS of those treated with chemotherapy (<i<n</i< = 54) and those treated with immunochemotherapy (<i<n</i< = 31) was 6.5 mon vs. 5.0 mon (<i<p</i< = 0.066). In the EGFR Ex20ins subgroup, the PFS of addition of bevacizumab to chemotherapy (<i<n</i< = 20) and chemotherapy alone (<i<n</i< = 16) was 8.8 mon and 5.2 mon, respectively (<i<p</i< = 0.082) or immunochemotherapy (<i<n</i< = 15, 8.8 mon and 5.0 mon, <i<p</i< = 0.097). Similarly, in the ERBB2 subgroup, the combination of bevacizumab and chemotherapy achieved a numerically longer PFS over chemotherapy alone (9.1 mon and 4.5 mon, <i<p</i< = 0.253), but there was no statistical significance. Conclusions: This study showed that platinum-based chemotherapy plus ICIs had limited efficiency compared to platinum-based chemotherapy for patients with EGFR/ERBB2 Ex20ins. Chemotherapy plus bevacizumab may be a potential scheme for these patients. Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Yue Zheng [verfasserIn] Yang Fu [verfasserIn] Yueyun Chen [verfasserIn] Qing Li [verfasserIn] Ting Liu [verfasserIn] Zhenyu Ding [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2023

Schlagwörter:	EGFR ERBB2 exon 20 insertion immunochemotherapy lung cancer

Übergeordnetes Werk:	In: Current Oncology - MDPI AG, 2021, 30(2023), 11, Seite 9929-9939
Übergeordnetes Werk:	volume:30 ; year:2023 ; number:11 ; pages:9929-9939

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.3390/curroncol30110721

Katalog-ID:	DOAJ101257260

Internformat


LEADER	01000naa a22002652 4500
001	DOAJ101257260
003	DE-627
005	20240414152947.0
007	cr uuu---uuuuu
008	240414s2023 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.3390/curroncol30110721 \|2 doi
035			\|a (DE-627)DOAJ101257260
035			\|a (DE-599)DOAJ8ea350d643ec478b94d0a1ab205e11db
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC254-282
100	0		\|a Yue Zheng \|e verfasserin \|4 aut
245	1	0	\|a Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Background: EGFR and ERBB2 exon 20 insertion (Ex20ins) account for a small fraction of patients with EGFR mutations. The efficacy of immune checkpoint inhibitors (ICIs) for these patients was still controversial. Methods: This retrospective study enrolled lung cancer patients harboring either EGFR or ERBB2 Ex20ins mutations. All the patients were treated with platinum-based chemotherapy plus ICIs, or platinum-based chemotherapy. The demographic features and clinical outcome of each patient were reviewed and analyzed. Results: When treated with immunochemotherapy, patients with EGFR/ERBB2 Ex20ins mutations (<i<n</i< = 31) had poor PFS compared with those without EGFR mutations (<i<n</i< = 141, 5.0 mon and 11.2 mon, <i<p</i< < 0.001). When compared with those with EGFR classic mutations who received immunotherapy as the salvage therapy (<i<n</i< = 24), these patients with EGFR/ERBB2 Ex20ins mutations had similar PFS (5.0 mon and 4.1 mon, <i<p</i< = 0.625), ORR (37.5% vs. 48.4%), and DCR (70.8% vs. 77.4%). In the patients with EGFR/ERBB2 Ex20ins mutations, the PFS of those treated with chemotherapy (<i<n</i< = 54) and those treated with immunochemotherapy (<i<n</i< = 31) was 6.5 mon vs. 5.0 mon (<i<p</i< = 0.066). In the EGFR Ex20ins subgroup, the PFS of addition of bevacizumab to chemotherapy (<i<n</i< = 20) and chemotherapy alone (<i<n</i< = 16) was 8.8 mon and 5.2 mon, respectively (<i<p</i< = 0.082) or immunochemotherapy (<i<n</i< = 15, 8.8 mon and 5.0 mon, <i<p</i< = 0.097). Similarly, in the ERBB2 subgroup, the combination of bevacizumab and chemotherapy achieved a numerically longer PFS over chemotherapy alone (9.1 mon and 4.5 mon, <i<p</i< = 0.253), but there was no statistical significance. Conclusions: This study showed that platinum-based chemotherapy plus ICIs had limited efficiency compared to platinum-based chemotherapy for patients with EGFR/ERBB2 Ex20ins. Chemotherapy plus bevacizumab may be a potential scheme for these patients.
650		4	\|a EGFR
650		4	\|a ERBB2
650		4	\|a exon 20 insertion
650		4	\|a immunochemotherapy
650		4	\|a lung cancer
653		0	\|a Neoplasms. Tumors. Oncology. Including cancer and carcinogens
700	0		\|a Yang Fu \|e verfasserin \|4 aut
700	0		\|a Yueyun Chen \|e verfasserin \|4 aut
700	0		\|a Qing Li \|e verfasserin \|4 aut
700	0		\|a Ting Liu \|e verfasserin \|4 aut
700	0		\|a Zhenyu Ding \|e verfasserin \|4 aut
773	0	8	\|i In \|t Current Oncology \|d MDPI AG, 2021 \|g 30(2023), 11, Seite 9929-9939 \|w (DE-627)524623112 \|w (DE-600)2270777-3 \|x 17187729 \|7 nnns
773	1	8	\|g volume:30 \|g year:2023 \|g number:11 \|g pages:9929-9939
856	4	0	\|u https://doi.org/10.3390/curroncol30110721 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/8ea350d643ec478b94d0a1ab205e11db \|z kostenfrei
856	4	0	\|u https://www.mdpi.com/1718-7729/30/11/721 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1198-0052 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1718-7729 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 30 \|j 2023 \|e 11 \|h 9929-9939

Indexfelder

author_variant	y z yz y f yf y c yc q l ql t l tl z d zd
matchkey_str	article:17187729:2023----::orfiayfmuehcpitniioslshmteaynugacrainsi
hierarchy_sort_str	2023
callnumber-subject-code	RC
publishDate	2023
allfields	10.3390/curroncol30110721 doi (DE-627)DOAJ101257260 (DE-599)DOAJ8ea350d643ec478b94d0a1ab205e11db DE-627 ger DE-627 rakwb eng RC254-282 Yue Zheng verfasserin aut Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: EGFR and ERBB2 exon 20 insertion (Ex20ins) account for a small fraction of patients with EGFR mutations. The efficacy of immune checkpoint inhibitors (ICIs) for these patients was still controversial. Methods: This retrospective study enrolled lung cancer patients harboring either EGFR or ERBB2 Ex20ins mutations. All the patients were treated with platinum-based chemotherapy plus ICIs, or platinum-based chemotherapy. The demographic features and clinical outcome of each patient were reviewed and analyzed. Results: When treated with immunochemotherapy, patients with EGFR/ERBB2 Ex20ins mutations (<i<n</i< = 31) had poor PFS compared with those without EGFR mutations (<i<n</i< = 141, 5.0 mon and 11.2 mon, <i<p</i< < 0.001). When compared with those with EGFR classic mutations who received immunotherapy as the salvage therapy (<i<n</i< = 24), these patients with EGFR/ERBB2 Ex20ins mutations had similar PFS (5.0 mon and 4.1 mon, <i<p</i< = 0.625), ORR (37.5% vs. 48.4%), and DCR (70.8% vs. 77.4%). In the patients with EGFR/ERBB2 Ex20ins mutations, the PFS of those treated with chemotherapy (<i<n</i< = 54) and those treated with immunochemotherapy (<i<n</i< = 31) was 6.5 mon vs. 5.0 mon (<i<p</i< = 0.066). In the EGFR Ex20ins subgroup, the PFS of addition of bevacizumab to chemotherapy (<i<n</i< = 20) and chemotherapy alone (<i<n</i< = 16) was 8.8 mon and 5.2 mon, respectively (<i<p</i< = 0.082) or immunochemotherapy (<i<n</i< = 15, 8.8 mon and 5.0 mon, <i<p</i< = 0.097). Similarly, in the ERBB2 subgroup, the combination of bevacizumab and chemotherapy achieved a numerically longer PFS over chemotherapy alone (9.1 mon and 4.5 mon, <i<p</i< = 0.253), but there was no statistical significance. Conclusions: This study showed that platinum-based chemotherapy plus ICIs had limited efficiency compared to platinum-based chemotherapy for patients with EGFR/ERBB2 Ex20ins. Chemotherapy plus bevacizumab may be a potential scheme for these patients. EGFR ERBB2 exon 20 insertion immunochemotherapy lung cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens Yang Fu verfasserin aut Yueyun Chen verfasserin aut Qing Li verfasserin aut Ting Liu verfasserin aut Zhenyu Ding verfasserin aut In Current Oncology MDPI AG, 2021 30(2023), 11, Seite 9929-9939 (DE-627)524623112 (DE-600)2270777-3 17187729 nnns volume:30 year:2023 number:11 pages:9929-9939 https://doi.org/10.3390/curroncol30110721 kostenfrei https://doaj.org/article/8ea350d643ec478b94d0a1ab205e11db kostenfrei https://www.mdpi.com/1718-7729/30/11/721 kostenfrei https://doaj.org/toc/1198-0052 Journal toc kostenfrei https://doaj.org/toc/1718-7729 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2106 GBV_ILN_2111 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 30 2023 11 9929-9939
spelling	10.3390/curroncol30110721 doi (DE-627)DOAJ101257260 (DE-599)DOAJ8ea350d643ec478b94d0a1ab205e11db DE-627 ger DE-627 rakwb eng RC254-282 Yue Zheng verfasserin aut Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: EGFR and ERBB2 exon 20 insertion (Ex20ins) account for a small fraction of patients with EGFR mutations. The efficacy of immune checkpoint inhibitors (ICIs) for these patients was still controversial. Methods: This retrospective study enrolled lung cancer patients harboring either EGFR or ERBB2 Ex20ins mutations. All the patients were treated with platinum-based chemotherapy plus ICIs, or platinum-based chemotherapy. The demographic features and clinical outcome of each patient were reviewed and analyzed. Results: When treated with immunochemotherapy, patients with EGFR/ERBB2 Ex20ins mutations (<i<n</i< = 31) had poor PFS compared with those without EGFR mutations (<i<n</i< = 141, 5.0 mon and 11.2 mon, <i<p</i< < 0.001). When compared with those with EGFR classic mutations who received immunotherapy as the salvage therapy (<i<n</i< = 24), these patients with EGFR/ERBB2 Ex20ins mutations had similar PFS (5.0 mon and 4.1 mon, <i<p</i< = 0.625), ORR (37.5% vs. 48.4%), and DCR (70.8% vs. 77.4%). In the patients with EGFR/ERBB2 Ex20ins mutations, the PFS of those treated with chemotherapy (<i<n</i< = 54) and those treated with immunochemotherapy (<i<n</i< = 31) was 6.5 mon vs. 5.0 mon (<i<p</i< = 0.066). In the EGFR Ex20ins subgroup, the PFS of addition of bevacizumab to chemotherapy (<i<n</i< = 20) and chemotherapy alone (<i<n</i< = 16) was 8.8 mon and 5.2 mon, respectively (<i<p</i< = 0.082) or immunochemotherapy (<i<n</i< = 15, 8.8 mon and 5.0 mon, <i<p</i< = 0.097). Similarly, in the ERBB2 subgroup, the combination of bevacizumab and chemotherapy achieved a numerically longer PFS over chemotherapy alone (9.1 mon and 4.5 mon, <i<p</i< = 0.253), but there was no statistical significance. Conclusions: This study showed that platinum-based chemotherapy plus ICIs had limited efficiency compared to platinum-based chemotherapy for patients with EGFR/ERBB2 Ex20ins. Chemotherapy plus bevacizumab may be a potential scheme for these patients. EGFR ERBB2 exon 20 insertion immunochemotherapy lung cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens Yang Fu verfasserin aut Yueyun Chen verfasserin aut Qing Li verfasserin aut Ting Liu verfasserin aut Zhenyu Ding verfasserin aut In Current Oncology MDPI AG, 2021 30(2023), 11, Seite 9929-9939 (DE-627)524623112 (DE-600)2270777-3 17187729 nnns volume:30 year:2023 number:11 pages:9929-9939 https://doi.org/10.3390/curroncol30110721 kostenfrei https://doaj.org/article/8ea350d643ec478b94d0a1ab205e11db kostenfrei https://www.mdpi.com/1718-7729/30/11/721 kostenfrei https://doaj.org/toc/1198-0052 Journal toc kostenfrei https://doaj.org/toc/1718-7729 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2106 GBV_ILN_2111 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 30 2023 11 9929-9939
allfields_unstemmed	10.3390/curroncol30110721 doi (DE-627)DOAJ101257260 (DE-599)DOAJ8ea350d643ec478b94d0a1ab205e11db DE-627 ger DE-627 rakwb eng RC254-282 Yue Zheng verfasserin aut Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: EGFR and ERBB2 exon 20 insertion (Ex20ins) account for a small fraction of patients with EGFR mutations. The efficacy of immune checkpoint inhibitors (ICIs) for these patients was still controversial. Methods: This retrospective study enrolled lung cancer patients harboring either EGFR or ERBB2 Ex20ins mutations. All the patients were treated with platinum-based chemotherapy plus ICIs, or platinum-based chemotherapy. The demographic features and clinical outcome of each patient were reviewed and analyzed. Results: When treated with immunochemotherapy, patients with EGFR/ERBB2 Ex20ins mutations (<i<n</i< = 31) had poor PFS compared with those without EGFR mutations (<i<n</i< = 141, 5.0 mon and 11.2 mon, <i<p</i< < 0.001). When compared with those with EGFR classic mutations who received immunotherapy as the salvage therapy (<i<n</i< = 24), these patients with EGFR/ERBB2 Ex20ins mutations had similar PFS (5.0 mon and 4.1 mon, <i<p</i< = 0.625), ORR (37.5% vs. 48.4%), and DCR (70.8% vs. 77.4%). In the patients with EGFR/ERBB2 Ex20ins mutations, the PFS of those treated with chemotherapy (<i<n</i< = 54) and those treated with immunochemotherapy (<i<n</i< = 31) was 6.5 mon vs. 5.0 mon (<i<p</i< = 0.066). In the EGFR Ex20ins subgroup, the PFS of addition of bevacizumab to chemotherapy (<i<n</i< = 20) and chemotherapy alone (<i<n</i< = 16) was 8.8 mon and 5.2 mon, respectively (<i<p</i< = 0.082) or immunochemotherapy (<i<n</i< = 15, 8.8 mon and 5.0 mon, <i<p</i< = 0.097). Similarly, in the ERBB2 subgroup, the combination of bevacizumab and chemotherapy achieved a numerically longer PFS over chemotherapy alone (9.1 mon and 4.5 mon, <i<p</i< = 0.253), but there was no statistical significance. Conclusions: This study showed that platinum-based chemotherapy plus ICIs had limited efficiency compared to platinum-based chemotherapy for patients with EGFR/ERBB2 Ex20ins. Chemotherapy plus bevacizumab may be a potential scheme for these patients. EGFR ERBB2 exon 20 insertion immunochemotherapy lung cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens Yang Fu verfasserin aut Yueyun Chen verfasserin aut Qing Li verfasserin aut Ting Liu verfasserin aut Zhenyu Ding verfasserin aut In Current Oncology MDPI AG, 2021 30(2023), 11, Seite 9929-9939 (DE-627)524623112 (DE-600)2270777-3 17187729 nnns volume:30 year:2023 number:11 pages:9929-9939 https://doi.org/10.3390/curroncol30110721 kostenfrei https://doaj.org/article/8ea350d643ec478b94d0a1ab205e11db kostenfrei https://www.mdpi.com/1718-7729/30/11/721 kostenfrei https://doaj.org/toc/1198-0052 Journal toc kostenfrei https://doaj.org/toc/1718-7729 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2106 GBV_ILN_2111 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 30 2023 11 9929-9939
allfieldsGer	10.3390/curroncol30110721 doi (DE-627)DOAJ101257260 (DE-599)DOAJ8ea350d643ec478b94d0a1ab205e11db DE-627 ger DE-627 rakwb eng RC254-282 Yue Zheng verfasserin aut Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: EGFR and ERBB2 exon 20 insertion (Ex20ins) account for a small fraction of patients with EGFR mutations. The efficacy of immune checkpoint inhibitors (ICIs) for these patients was still controversial. Methods: This retrospective study enrolled lung cancer patients harboring either EGFR or ERBB2 Ex20ins mutations. All the patients were treated with platinum-based chemotherapy plus ICIs, or platinum-based chemotherapy. The demographic features and clinical outcome of each patient were reviewed and analyzed. Results: When treated with immunochemotherapy, patients with EGFR/ERBB2 Ex20ins mutations (<i<n</i< = 31) had poor PFS compared with those without EGFR mutations (<i<n</i< = 141, 5.0 mon and 11.2 mon, <i<p</i< < 0.001). When compared with those with EGFR classic mutations who received immunotherapy as the salvage therapy (<i<n</i< = 24), these patients with EGFR/ERBB2 Ex20ins mutations had similar PFS (5.0 mon and 4.1 mon, <i<p</i< = 0.625), ORR (37.5% vs. 48.4%), and DCR (70.8% vs. 77.4%). In the patients with EGFR/ERBB2 Ex20ins mutations, the PFS of those treated with chemotherapy (<i<n</i< = 54) and those treated with immunochemotherapy (<i<n</i< = 31) was 6.5 mon vs. 5.0 mon (<i<p</i< = 0.066). In the EGFR Ex20ins subgroup, the PFS of addition of bevacizumab to chemotherapy (<i<n</i< = 20) and chemotherapy alone (<i<n</i< = 16) was 8.8 mon and 5.2 mon, respectively (<i<p</i< = 0.082) or immunochemotherapy (<i<n</i< = 15, 8.8 mon and 5.0 mon, <i<p</i< = 0.097). Similarly, in the ERBB2 subgroup, the combination of bevacizumab and chemotherapy achieved a numerically longer PFS over chemotherapy alone (9.1 mon and 4.5 mon, <i<p</i< = 0.253), but there was no statistical significance. Conclusions: This study showed that platinum-based chemotherapy plus ICIs had limited efficiency compared to platinum-based chemotherapy for patients with EGFR/ERBB2 Ex20ins. Chemotherapy plus bevacizumab may be a potential scheme for these patients. EGFR ERBB2 exon 20 insertion immunochemotherapy lung cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens Yang Fu verfasserin aut Yueyun Chen verfasserin aut Qing Li verfasserin aut Ting Liu verfasserin aut Zhenyu Ding verfasserin aut In Current Oncology MDPI AG, 2021 30(2023), 11, Seite 9929-9939 (DE-627)524623112 (DE-600)2270777-3 17187729 nnns volume:30 year:2023 number:11 pages:9929-9939 https://doi.org/10.3390/curroncol30110721 kostenfrei https://doaj.org/article/8ea350d643ec478b94d0a1ab205e11db kostenfrei https://www.mdpi.com/1718-7729/30/11/721 kostenfrei https://doaj.org/toc/1198-0052 Journal toc kostenfrei https://doaj.org/toc/1718-7729 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2106 GBV_ILN_2111 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 30 2023 11 9929-9939
allfieldsSound	10.3390/curroncol30110721 doi (DE-627)DOAJ101257260 (DE-599)DOAJ8ea350d643ec478b94d0a1ab205e11db DE-627 ger DE-627 rakwb eng RC254-282 Yue Zheng verfasserin aut Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: EGFR and ERBB2 exon 20 insertion (Ex20ins) account for a small fraction of patients with EGFR mutations. The efficacy of immune checkpoint inhibitors (ICIs) for these patients was still controversial. Methods: This retrospective study enrolled lung cancer patients harboring either EGFR or ERBB2 Ex20ins mutations. All the patients were treated with platinum-based chemotherapy plus ICIs, or platinum-based chemotherapy. The demographic features and clinical outcome of each patient were reviewed and analyzed. Results: When treated with immunochemotherapy, patients with EGFR/ERBB2 Ex20ins mutations (<i<n</i< = 31) had poor PFS compared with those without EGFR mutations (<i<n</i< = 141, 5.0 mon and 11.2 mon, <i<p</i< < 0.001). When compared with those with EGFR classic mutations who received immunotherapy as the salvage therapy (<i<n</i< = 24), these patients with EGFR/ERBB2 Ex20ins mutations had similar PFS (5.0 mon and 4.1 mon, <i<p</i< = 0.625), ORR (37.5% vs. 48.4%), and DCR (70.8% vs. 77.4%). In the patients with EGFR/ERBB2 Ex20ins mutations, the PFS of those treated with chemotherapy (<i<n</i< = 54) and those treated with immunochemotherapy (<i<n</i< = 31) was 6.5 mon vs. 5.0 mon (<i<p</i< = 0.066). In the EGFR Ex20ins subgroup, the PFS of addition of bevacizumab to chemotherapy (<i<n</i< = 20) and chemotherapy alone (<i<n</i< = 16) was 8.8 mon and 5.2 mon, respectively (<i<p</i< = 0.082) or immunochemotherapy (<i<n</i< = 15, 8.8 mon and 5.0 mon, <i<p</i< = 0.097). Similarly, in the ERBB2 subgroup, the combination of bevacizumab and chemotherapy achieved a numerically longer PFS over chemotherapy alone (9.1 mon and 4.5 mon, <i<p</i< = 0.253), but there was no statistical significance. Conclusions: This study showed that platinum-based chemotherapy plus ICIs had limited efficiency compared to platinum-based chemotherapy for patients with EGFR/ERBB2 Ex20ins. Chemotherapy plus bevacizumab may be a potential scheme for these patients. EGFR ERBB2 exon 20 insertion immunochemotherapy lung cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens Yang Fu verfasserin aut Yueyun Chen verfasserin aut Qing Li verfasserin aut Ting Liu verfasserin aut Zhenyu Ding verfasserin aut In Current Oncology MDPI AG, 2021 30(2023), 11, Seite 9929-9939 (DE-627)524623112 (DE-600)2270777-3 17187729 nnns volume:30 year:2023 number:11 pages:9929-9939 https://doi.org/10.3390/curroncol30110721 kostenfrei https://doaj.org/article/8ea350d643ec478b94d0a1ab205e11db kostenfrei https://www.mdpi.com/1718-7729/30/11/721 kostenfrei https://doaj.org/toc/1198-0052 Journal toc kostenfrei https://doaj.org/toc/1718-7729 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2106 GBV_ILN_2111 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 30 2023 11 9929-9939
language	English
source	In Current Oncology 30(2023), 11, Seite 9929-9939 volume:30 year:2023 number:11 pages:9929-9939
sourceStr	In Current Oncology 30(2023), 11, Seite 9929-9939 volume:30 year:2023 number:11 pages:9929-9939
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	EGFR ERBB2 exon 20 insertion immunochemotherapy lung cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens
isfreeaccess_bool	true
container_title	Current Oncology
authorswithroles_txt_mv	Yue Zheng @@aut@@ Yang Fu @@aut@@ Yueyun Chen @@aut@@ Qing Li @@aut@@ Ting Liu @@aut@@ Zhenyu Ding @@aut@@
publishDateDaySort_date	2023-01-01T00:00:00Z
hierarchy_top_id	524623112
id	DOAJ101257260
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ101257260</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414152947.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240414s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/curroncol30110721</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ101257260</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ8ea350d643ec478b94d0a1ab205e11db</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Yue Zheng</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: EGFR and ERBB2 exon 20 insertion (Ex20ins) account for a small fraction of patients with EGFR mutations. The efficacy of immune checkpoint inhibitors (ICIs) for these patients was still controversial. Methods: This retrospective study enrolled lung cancer patients harboring either EGFR or ERBB2 Ex20ins mutations. All the patients were treated with platinum-based chemotherapy plus ICIs, or platinum-based chemotherapy. The demographic features and clinical outcome of each patient were reviewed and analyzed. Results: When treated with immunochemotherapy, patients with EGFR/ERBB2 Ex20ins mutations (<i<n</i< = 31) had poor PFS compared with those without EGFR mutations (<i<n</i< = 141, 5.0 mon and 11.2 mon, <i<p</i< < 0.001). When compared with those with EGFR classic mutations who received immunotherapy as the salvage therapy (<i<n</i< = 24), these patients with EGFR/ERBB2 Ex20ins mutations had similar PFS (5.0 mon and 4.1 mon, <i<p</i< = 0.625), ORR (37.5% vs. 48.4%), and DCR (70.8% vs. 77.4%). In the patients with EGFR/ERBB2 Ex20ins mutations, the PFS of those treated with chemotherapy (<i<n</i< = 54) and those treated with immunochemotherapy (<i<n</i< = 31) was 6.5 mon vs. 5.0 mon (<i<p</i< = 0.066). In the EGFR Ex20ins subgroup, the PFS of addition of bevacizumab to chemotherapy (<i<n</i< = 20) and chemotherapy alone (<i<n</i< = 16) was 8.8 mon and 5.2 mon, respectively (<i<p</i< = 0.082) or immunochemotherapy (<i<n</i< = 15, 8.8 mon and 5.0 mon, <i<p</i< = 0.097). Similarly, in the ERBB2 subgroup, the combination of bevacizumab and chemotherapy achieved a numerically longer PFS over chemotherapy alone (9.1 mon and 4.5 mon, <i<p</i< = 0.253), but there was no statistical significance. Conclusions: This study showed that platinum-based chemotherapy plus ICIs had limited efficiency compared to platinum-based chemotherapy for patients with EGFR/ERBB2 Ex20ins. Chemotherapy plus bevacizumab may be a potential scheme for these patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">EGFR</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ERBB2</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">exon 20 insertion</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immunochemotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">lung cancer</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yang Fu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yueyun Chen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Qing Li</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ting Liu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zhenyu Ding</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Current Oncology</subfield><subfield code="d">MDPI AG, 2021</subfield><subfield code="g">30(2023), 11, Seite 9929-9939</subfield><subfield code="w">(DE-627)524623112</subfield><subfield code="w">(DE-600)2270777-3</subfield><subfield code="x">17187729</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:30</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:11</subfield><subfield code="g">pages:9929-9939</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/curroncol30110721</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/8ea350d643ec478b94d0a1ab205e11db</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/1718-7729/30/11/721</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1198-0052</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1718-7729</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">30</subfield><subfield code="j">2023</subfield><subfield code="e">11</subfield><subfield code="h">9929-9939</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Yue Zheng
spellingShingle	Yue Zheng misc RC254-282 misc EGFR misc ERBB2 misc exon 20 insertion misc immunochemotherapy misc lung cancer misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion
authorStr	Yue Zheng
ppnlink_with_tag_str_mv	@@773@@(DE-627)524623112
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC254-282
illustrated	Not Illustrated
issn	17187729
topic_title	RC254-282 Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion EGFR ERBB2 exon 20 insertion immunochemotherapy lung cancer
topic	misc RC254-282 misc EGFR misc ERBB2 misc exon 20 insertion misc immunochemotherapy misc lung cancer misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_unstemmed	misc RC254-282 misc EGFR misc ERBB2 misc exon 20 insertion misc immunochemotherapy misc lung cancer misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_browse	misc RC254-282 misc EGFR misc ERBB2 misc exon 20 insertion misc immunochemotherapy misc lung cancer misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Current Oncology
hierarchy_parent_id	524623112
hierarchy_top_title	Current Oncology
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)524623112 (DE-600)2270777-3
title	Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion
ctrlnum	(DE-627)DOAJ101257260 (DE-599)DOAJ8ea350d643ec478b94d0a1ab205e11db
title_full	Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion
author_sort	Yue Zheng
journal	Current Oncology
journalStr	Current Oncology
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2023
contenttype_str_mv	txt
container_start_page	9929
author_browse	Yue Zheng Yang Fu Yueyun Chen Qing Li Ting Liu Zhenyu Ding
container_volume	30
class	RC254-282
format_se	Elektronische Aufsätze
author-letter	Yue Zheng
doi_str_mv	10.3390/curroncol30110721
author2-role	verfasserin
title_sort	poor efficacy of immune checkpoint inhibitors plus chemotherapy in lung cancer patients with egfr/erbb2 exon 20 insertion
callnumber	RC254-282
title_auth	Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion
abstract	Background: EGFR and ERBB2 exon 20 insertion (Ex20ins) account for a small fraction of patients with EGFR mutations. The efficacy of immune checkpoint inhibitors (ICIs) for these patients was still controversial. Methods: This retrospective study enrolled lung cancer patients harboring either EGFR or ERBB2 Ex20ins mutations. All the patients were treated with platinum-based chemotherapy plus ICIs, or platinum-based chemotherapy. The demographic features and clinical outcome of each patient were reviewed and analyzed. Results: When treated with immunochemotherapy, patients with EGFR/ERBB2 Ex20ins mutations (<i<n</i< = 31) had poor PFS compared with those without EGFR mutations (<i<n</i< = 141, 5.0 mon and 11.2 mon, <i<p</i< < 0.001). When compared with those with EGFR classic mutations who received immunotherapy as the salvage therapy (<i<n</i< = 24), these patients with EGFR/ERBB2 Ex20ins mutations had similar PFS (5.0 mon and 4.1 mon, <i<p</i< = 0.625), ORR (37.5% vs. 48.4%), and DCR (70.8% vs. 77.4%). In the patients with EGFR/ERBB2 Ex20ins mutations, the PFS of those treated with chemotherapy (<i<n</i< = 54) and those treated with immunochemotherapy (<i<n</i< = 31) was 6.5 mon vs. 5.0 mon (<i<p</i< = 0.066). In the EGFR Ex20ins subgroup, the PFS of addition of bevacizumab to chemotherapy (<i<n</i< = 20) and chemotherapy alone (<i<n</i< = 16) was 8.8 mon and 5.2 mon, respectively (<i<p</i< = 0.082) or immunochemotherapy (<i<n</i< = 15, 8.8 mon and 5.0 mon, <i<p</i< = 0.097). Similarly, in the ERBB2 subgroup, the combination of bevacizumab and chemotherapy achieved a numerically longer PFS over chemotherapy alone (9.1 mon and 4.5 mon, <i<p</i< = 0.253), but there was no statistical significance. Conclusions: This study showed that platinum-based chemotherapy plus ICIs had limited efficiency compared to platinum-based chemotherapy for patients with EGFR/ERBB2 Ex20ins. Chemotherapy plus bevacizumab may be a potential scheme for these patients.
abstractGer	Background: EGFR and ERBB2 exon 20 insertion (Ex20ins) account for a small fraction of patients with EGFR mutations. The efficacy of immune checkpoint inhibitors (ICIs) for these patients was still controversial. Methods: This retrospective study enrolled lung cancer patients harboring either EGFR or ERBB2 Ex20ins mutations. All the patients were treated with platinum-based chemotherapy plus ICIs, or platinum-based chemotherapy. The demographic features and clinical outcome of each patient were reviewed and analyzed. Results: When treated with immunochemotherapy, patients with EGFR/ERBB2 Ex20ins mutations (<i<n</i< = 31) had poor PFS compared with those without EGFR mutations (<i<n</i< = 141, 5.0 mon and 11.2 mon, <i<p</i< < 0.001). When compared with those with EGFR classic mutations who received immunotherapy as the salvage therapy (<i<n</i< = 24), these patients with EGFR/ERBB2 Ex20ins mutations had similar PFS (5.0 mon and 4.1 mon, <i<p</i< = 0.625), ORR (37.5% vs. 48.4%), and DCR (70.8% vs. 77.4%). In the patients with EGFR/ERBB2 Ex20ins mutations, the PFS of those treated with chemotherapy (<i<n</i< = 54) and those treated with immunochemotherapy (<i<n</i< = 31) was 6.5 mon vs. 5.0 mon (<i<p</i< = 0.066). In the EGFR Ex20ins subgroup, the PFS of addition of bevacizumab to chemotherapy (<i<n</i< = 20) and chemotherapy alone (<i<n</i< = 16) was 8.8 mon and 5.2 mon, respectively (<i<p</i< = 0.082) or immunochemotherapy (<i<n</i< = 15, 8.8 mon and 5.0 mon, <i<p</i< = 0.097). Similarly, in the ERBB2 subgroup, the combination of bevacizumab and chemotherapy achieved a numerically longer PFS over chemotherapy alone (9.1 mon and 4.5 mon, <i<p</i< = 0.253), but there was no statistical significance. Conclusions: This study showed that platinum-based chemotherapy plus ICIs had limited efficiency compared to platinum-based chemotherapy for patients with EGFR/ERBB2 Ex20ins. Chemotherapy plus bevacizumab may be a potential scheme for these patients.
abstract_unstemmed	Background: EGFR and ERBB2 exon 20 insertion (Ex20ins) account for a small fraction of patients with EGFR mutations. The efficacy of immune checkpoint inhibitors (ICIs) for these patients was still controversial. Methods: This retrospective study enrolled lung cancer patients harboring either EGFR or ERBB2 Ex20ins mutations. All the patients were treated with platinum-based chemotherapy plus ICIs, or platinum-based chemotherapy. The demographic features and clinical outcome of each patient were reviewed and analyzed. Results: When treated with immunochemotherapy, patients with EGFR/ERBB2 Ex20ins mutations (<i<n</i< = 31) had poor PFS compared with those without EGFR mutations (<i<n</i< = 141, 5.0 mon and 11.2 mon, <i<p</i< < 0.001). When compared with those with EGFR classic mutations who received immunotherapy as the salvage therapy (<i<n</i< = 24), these patients with EGFR/ERBB2 Ex20ins mutations had similar PFS (5.0 mon and 4.1 mon, <i<p</i< = 0.625), ORR (37.5% vs. 48.4%), and DCR (70.8% vs. 77.4%). In the patients with EGFR/ERBB2 Ex20ins mutations, the PFS of those treated with chemotherapy (<i<n</i< = 54) and those treated with immunochemotherapy (<i<n</i< = 31) was 6.5 mon vs. 5.0 mon (<i<p</i< = 0.066). In the EGFR Ex20ins subgroup, the PFS of addition of bevacizumab to chemotherapy (<i<n</i< = 20) and chemotherapy alone (<i<n</i< = 16) was 8.8 mon and 5.2 mon, respectively (<i<p</i< = 0.082) or immunochemotherapy (<i<n</i< = 15, 8.8 mon and 5.0 mon, <i<p</i< = 0.097). Similarly, in the ERBB2 subgroup, the combination of bevacizumab and chemotherapy achieved a numerically longer PFS over chemotherapy alone (9.1 mon and 4.5 mon, <i<p</i< = 0.253), but there was no statistical significance. Conclusions: This study showed that platinum-based chemotherapy plus ICIs had limited efficiency compared to platinum-based chemotherapy for patients with EGFR/ERBB2 Ex20ins. Chemotherapy plus bevacizumab may be a potential scheme for these patients.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2106 GBV_ILN_2111 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	11
title_short	Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion
url	https://doi.org/10.3390/curroncol30110721 https://doaj.org/article/8ea350d643ec478b94d0a1ab205e11db https://www.mdpi.com/1718-7729/30/11/721 https://doaj.org/toc/1198-0052 https://doaj.org/toc/1718-7729
remote_bool	true
author2	Yang Fu Yueyun Chen Qing Li Ting Liu Zhenyu Ding
author2Str	Yang Fu Yueyun Chen Qing Li Ting Liu Zhenyu Ding
ppnlink	524623112
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3390/curroncol30110721
callnumber-a	RC254-282
up_date	2024-07-03T19:36:44.387Z
_version_	1803587844191551488
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ101257260</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414152947.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240414s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/curroncol30110721</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ101257260</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ8ea350d643ec478b94d0a1ab205e11db</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Yue Zheng</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: EGFR and ERBB2 exon 20 insertion (Ex20ins) account for a small fraction of patients with EGFR mutations. The efficacy of immune checkpoint inhibitors (ICIs) for these patients was still controversial. Methods: This retrospective study enrolled lung cancer patients harboring either EGFR or ERBB2 Ex20ins mutations. All the patients were treated with platinum-based chemotherapy plus ICIs, or platinum-based chemotherapy. The demographic features and clinical outcome of each patient were reviewed and analyzed. Results: When treated with immunochemotherapy, patients with EGFR/ERBB2 Ex20ins mutations (<i<n</i< = 31) had poor PFS compared with those without EGFR mutations (<i<n</i< = 141, 5.0 mon and 11.2 mon, <i<p</i< < 0.001). When compared with those with EGFR classic mutations who received immunotherapy as the salvage therapy (<i<n</i< = 24), these patients with EGFR/ERBB2 Ex20ins mutations had similar PFS (5.0 mon and 4.1 mon, <i<p</i< = 0.625), ORR (37.5% vs. 48.4%), and DCR (70.8% vs. 77.4%). In the patients with EGFR/ERBB2 Ex20ins mutations, the PFS of those treated with chemotherapy (<i<n</i< = 54) and those treated with immunochemotherapy (<i<n</i< = 31) was 6.5 mon vs. 5.0 mon (<i<p</i< = 0.066). In the EGFR Ex20ins subgroup, the PFS of addition of bevacizumab to chemotherapy (<i<n</i< = 20) and chemotherapy alone (<i<n</i< = 16) was 8.8 mon and 5.2 mon, respectively (<i<p</i< = 0.082) or immunochemotherapy (<i<n</i< = 15, 8.8 mon and 5.0 mon, <i<p</i< = 0.097). Similarly, in the ERBB2 subgroup, the combination of bevacizumab and chemotherapy achieved a numerically longer PFS over chemotherapy alone (9.1 mon and 4.5 mon, <i<p</i< = 0.253), but there was no statistical significance. Conclusions: This study showed that platinum-based chemotherapy plus ICIs had limited efficiency compared to platinum-based chemotherapy for patients with EGFR/ERBB2 Ex20ins. Chemotherapy plus bevacizumab may be a potential scheme for these patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">EGFR</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ERBB2</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">exon 20 insertion</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immunochemotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">lung cancer</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yang Fu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yueyun Chen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Qing Li</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ting Liu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zhenyu Ding</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Current Oncology</subfield><subfield code="d">MDPI AG, 2021</subfield><subfield code="g">30(2023), 11, Seite 9929-9939</subfield><subfield code="w">(DE-627)524623112</subfield><subfield code="w">(DE-600)2270777-3</subfield><subfield code="x">17187729</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:30</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:11</subfield><subfield code="g">pages:9929-9939</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/curroncol30110721</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/8ea350d643ec478b94d0a1ab205e11db</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/1718-7729/30/11/721</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1198-0052</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1718-7729</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">30</subfield><subfield code="j">2023</subfield><subfield code="e">11</subfield><subfield code="h">9929-9939</subfield></datafield></record></collection>
score	7.400487

Nicht das Richtige dabei?

Schreiben Sie uns!

Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?